Floatz logo

Avapritinib

Advanced Systemic Mastocytosis

Blueprint Medicines CorporationSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Advanced Systemic Mastocytosis cohort.

Asset / SponsorPhaseRating
Brentuximab Vedotin
Jason Robert Gotlib
Phase 2B
Imatinib
Novartis Pharmaceuticals
Phase 2B
Denileukin Diftitox
M.D. Anderson Cancer Center
Phase 2CCC
Ibrutinib
Jason Robert Gotlib
Phase 2CCC
Bezuclastinib
Cogent Biosciences, Inc.
Phase 2CCC

View all 15 →

Same molecule, other indications

Avapritinib is also rated in:

gastrointestinal stromal tumorDormant
BB
Indicative ·
67 / 100
View asset →
aggressive systemic mastocytosisDormant
BB
Indicative ·
64 / 100
View asset →
systemic mastocytosis with an associated clonal hematologic non-mast cell lineage diseaseDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →